Axonics® to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Axonics, a medical technology company based in Irvine, California, announced its participation in three upcoming virtual investor conferences. The conferences include the Wells Fargo Healthcare Conference on September 9, 2021; the Morgan Stanley Healthcare Conference on September 13, 2021; and the Baird Healthcare Conference on September 15, 2021. The company specializes in developing products for bladder and bowel dysfunction, including a rechargeable sacral neuromodulation system and a urethral bulking agent. A webcast of the presentations will be available on their investor relations website.

IRVINE, Calif.--(BUSINESS WIRE)-- Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that senior management will present at the following virtual investor conferences:

Event: Wells Fargo Healthcare Conference
Date: Thursday, September 9, 2021
Time: 12:00 p.m. Eastern Time

Event: Morgan Stanley Healthcare Conference
Date: Monday, September 13, 2021
Time: 12:30 p.m. Eastern Time

Event: Baird Healthcare Conference
Date: Wednesday, September 15, 2021
Time: 1:25 p.m. Eastern Time

Interested parties may access a live and archived webcast of each fireside chat by visiting the Axonics investor relations website.

About Axonics

Based in Irvine, Calif., Axonics is a global medical technology company that is developing and commercializing novel products for patients with bladder and bowel dysfunction. The company’s rechargeable sacral neuromodulation (SNM) system provides patients suffering from overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy. In addition, Axonics’ best-in-class urethral bulking agent, Bulkamid^®, provides women suffering from stress urinary incontinence (SUI) with safe and durable symptom relief.

Overactive bladder affects an estimated 87 million adults in the U.S. and Europe, with an additional 40 million adults estimated to suffer from fecal incontinence. SUI affects an estimated 20 million women in the U.S. alone. Axonics’ clinically proven products are offered at hundreds of medical centers across the U.S. and abroad. Reimbursement coverage is well established in the U.S. and is a covered service in most European countries. For more information, visit www.axonics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210827005029/en/

Axonics contact:

Neil Bhalodkar

Investor Relations

949-336-5293

ir@axonics.com

Source: Axonics, Inc.

FAQ

What conferences will Axonics participate in September 2021?

Axonics will participate in the Wells Fargo Healthcare Conference on September 9, 2021, the Morgan Stanley Healthcare Conference on September 13, 2021, and the Baird Healthcare Conference on September 15, 2021.

What is the focus of Axonics' products?

Axonics focuses on developing products for the treatment of bladder and bowel dysfunction, including a rechargeable sacral neuromodulation system and Bulkamid for stress urinary incontinence.

What time will Axonics present at the Morgan Stanley Healthcare Conference?

Axonics will present at the Morgan Stanley Healthcare Conference on September 13, 2021, at 12:30 p.m. Eastern Time.

Where can I access Axonics' conference presentations?

You can access live and archived webcasts of Axonics' presentations on their investor relations website.

What is the estimated market for overactive bladder treatment?

Overactive bladder affects an estimated 87 million adults in the U.S. and Europe, with 40 million adults suffering from fecal incontinence.